{"id":"W3119851230","doi":"10.1016/j.cgh.2021.01.006","title":"Patients With Low Drug Levels or Antibodies to a Prior Anti–Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti–Tumor Necrosis Factor","year":2021,"lang":"en","type":"article","venue":"Clinical Gastroenterology and Hepatology","topic":"Immunodeficiency and Autoimmune Disorders","field":"Immunology and Microbiology","cited_by":29,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Western University; Mount Sinai Hospital","funders":"Samsung; National Institutes of Health; Ferring Pharmaceuticals; Shire; Crohn's and Colitis Foundation; American Gastroenterological Association; Leona M. and Harry B. Helmsley Charitable Trust; Israel National Road Safety Authority; AbbVie; Kenneth Rainin Foundation; U.S. Department of Defense; National Institute of Diabetes and Digestive and Kidney Diseases; Boehringer Ingelheim; Janssen Pharmaceuticals; Gilead Sciences; Takeda Pharmaceuticals U.S.A.; School of Public Health, University of California Berkeley; Pfizer; Roche","keywords":"Medicine; Antibody; Tumor necrosis factor alpha; Drug; Tumor necrosis factor α; Necrosis; Immunology; Pathology; Pharmacology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004253174,0.0009338634,0.002522867,0.0004143214,0.0007901643,0.00008936192,0.0007974716,0.0005407851,0.0004945245],"category_scores_gemma":[0.001545117,0.0007369933,0.0002997241,0.0006899662,0.001239242,0.0002090599,0.001078248,0.001073306,0.0004390546],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007598587,"about_ca_system_score_gemma":0.0004531001,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000169332,"about_ca_topic_score_gemma":0.0008036526,"domain_scores_codex":[0.9931996,0.0009715449,0.001789037,0.001897527,0.0001550363,0.001987273],"domain_scores_gemma":[0.9967908,0.0006470142,0.0005548252,0.0008872343,0.0008916943,0.0002284727],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004386687,0.001377152,0.9781545,0.000113677,0.0006026596,0.0002424549,0.002107516,0.000005496978,0.00955329,0.00003511478,0.001344823,0.002076621],"study_design_scores_gemma":[0.004572995,0.002377791,0.9790183,0.0002801025,0.000140821,0.0002249502,0.0008690088,0.000003225525,0.005515103,0.00001227375,0.006320513,0.0006649579],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9888333,0.0007567992,0.0005663605,0.005704929,0.001828041,0.001153067,0.0009779811,0.000166727,0.00001278167],"genre_scores_gemma":[0.97996,0.0001394886,0.0007737882,0.01812268,0.0000212943,0.000124689,0.0001768886,0.00008036844,0.000600799],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01241775,"threshold_uncertainty_score":0.9995081,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02581687621056559,"score_gpt":0.2927787168194055,"score_spread":0.2669618406088399,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}